Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models

Feven Tameire(FuelCell Energy (United States)), Nandita Bose(FuelCell Energy (United States)), Sharon Huang(Intellicell Biosciences (United States)), Sho Fujisawa(New York University), Maria Fumagalli(FuelCell Energy (United States)), Ben Harrison(FuelCell Energy (United States)), Jeremy Drees(FuelCell Energy (United States)), Savithri Ramurthy(FuelCell Energy (United States)), Paulina M. Wojnarowicz(Memorial Sloan Kettering Cancer Center), Anissa Chan(FuelCell Energy (United States)), Nicholas Collette(FuelCell Energy (United States)), Kathryn Bieging-Rolett(Stanford University), Alan C. Rigby(FuelCell Energy (United States)), Ashley LaCayo(FuelCell Energy (United States)), Owen Reilly(FuelCell Energy (United States)), David Surguladze(Intellicell Biosciences (United States)), Xiaohong Qiu(FuelCell Energy (United States)), Kirk A. Staschke(Indiana University Health), Ricardo A. Cordova(Indiana University Health), Iman Dewji(FuelCell Energy (United States)), Weiyu Zhang(Henan Normal University), Yunfang Li(FuelCell Energy (United States)), Eric S. Lightcap, Takashi Kangas(FuelCell Energy (United States)), Crissy Dudgeon(Rutgers, The State University of New Jersey)
Cancer Research
April 4, 2023
Cited by 3


Related Papers